Familial Hemiplegic Migraine Panel
Use
This test is intended for individuals with relevant clinical features or a suspected diagnosis of familial hemiplegic migraine (FHM). It is also recommended for individuals with a family history of hemiplegic migraine, involving first- or second-degree relatives. FHM is a rare form of migraine with aura, typically associated with varying levels of neurological symptoms including hemiplegia. Genetic testing aims to confirm the diagnosis and assist in clinical management, as well as guide family planning decisions.
Special Instructions
Ordering this test may require special institutional or healthcare provider accounts. The turnaround time for urgent testing (STAT) could extend up to 16 days if blood samples are delayed. A completed test requisition form and properly labeled specimens are necessary to initiate testing. Also, additional testing options are available post-report analysis, such as targeted family testing based on the initial report outcomes.
Limitations
Not every potential genetic cause of familial hemiplegic migraine is included in this test. Variants in genes not covered by the panel will not be detected. The test does not cover rare or unknown genes potentially associated with FHM and could result in false negatives for mutations outside the examined loci. Furthermore, this genetic test does not substitute clinical diagnosis or predict the complete spectrum of symptoms.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided